You are here:   Investor Relations

Investor Overview

Data as of 11/20/18 at 6:36 AM EST
Copyright Nasdaq. Minimum 15 minutes delayed.
High
Low
Volume

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

View all press releases

Press Releases

Date Title and Summary
Toggle Summary Rexahn Pharmaceuticals Announces Leadership Transition
Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, Md. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve outcomes in cancers that are difficult to treat, today
Toggle Summary Rexahn Reports Third Quarter 2018 Financial Results
ROCKVILLE, Md. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the three and nine months ended September 30,
Toggle Summary Rexahn Announces $7.5 Million Registered Direct Offering
ROCKVILLE, Md. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 5.77 million shares of its common stock and warrants exercisable for up to
View all events and presentations

Events & Presentations

Date Event Details
Summary Toggle Oct 2 - Oct 3, 2018

5th NCI Pancreatic Cancer Symposium

Title:  RX-3117, A NOVEL, ORAL NUCLEOSIDE ANALOG, IN COMBINATION WITH NAB-PACLITAXEL (NAB-PAC) IN FIRST-LINE METASTATIC PANCREATIC CANCER (MET-PC): SAFETY, TOLERABILITY AND PRELIMINARY RESPONSES   [View Poster]

Location

National Institutes of Health in Bethesda, Maryland
Summary Toggle Sep 6, 2018
9:35 AM EDT Sep 6, 2018 9:35 AM EDT 09/06/18

The 20th Annual Rodman & Renshaw Global Investment Conference
Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18

American Society of Clinical Oncology (ASCO) 2018 Annual Meeting - Chicago, IL

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy